Literature DB >> 18194479

Endothelial cells do not express GSTA1: potential relevance to busulfan-mediated endothelial damage during haematopoietic stem cell transplantation.

Camille Vassord1, Claudine Lapouméroulie, Kailasam Koumaravelou, Alok Srivastava, Rajagopal Krishnamoorthy.   

Abstract

Busulfan-mediated endothelial damage is believed to be a common mechanism in a variety of vascular disorders that occur during haematopoietic stem cell transplantation. The alkylating capacity of busulfan is compromised in vivo by enzymatic conjugation with glutathione, principally catalysed by glutathione S-transferase alpha (GST alpha). We investigated whether the susceptibility of endothelial cells to busulfan-mediated damage is related to their intrinsic deficiency in GST alpha expression. We tested for the expression of GST alpha mRNA by real-time quantitative PCR and the GST protein by enzyme-linked immunosorbent assay in various independently derived endothelial cell types (human bone marrow-derived endothelial cell line and endothelial cells from human vein umbilical cord ) and in a control hepatic cell line, HepG2. We demonstrate that endothelial cells, contrary to hepatic cells do not express GST alpha either at mRNA or protein levels and hence are potentially susceptible to busulfan-mediated cytotoxic damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18194479     DOI: 10.1111/j.1600-0609.2008.01031.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study.

Authors:  C Oudin; P Auquier; Y Bertrand; A Contet; J Kanold; N Sirvent; S Thouvenin; M-D Tabone; P Lutz; S Ducassou; D Plantaz; J-H Dalle; V Gandemer; S Beliard; J Berbis; C Vercasson; V Barlogis; A Baruchel; G Leverger; G Michel
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

2.  Successful unrelated umbilical cord blood transplantation in Lesch-Nyhan syndrome.

Authors:  Krisztián Kállay; Zoltán Liptai; Gábor Benyó; Csaba Kassa; Veronika Goda; János Sinkó; Agnes Tóth; Gergely Kriván
Journal:  Metab Brain Dis       Date:  2012-02-17       Impact factor: 3.584

3.  Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy.

Authors:  Lauren A Dalvin; Timothy W Olsen; Sophie J Bakri; Kristen McCullough; Ayalew Tefferi; Aref Al-Kali
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-21

Review 4.  Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.

Authors:  Rachael Lawson; Christine E Staatz; Christopher J Fraser; Stefanie Hennig
Journal:  Clin Pharmacokinet       Date:  2020-10-30       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.